The NAFLD patients included in this project were mild, and hepatocyte necrosis had not yet occurred (Fig. 1), enabling us to examine the change and role of KAL in the early stages of the disease. This evidence concerns the gene SERPINA4 and metabolic dysfunction-associated steatotic liver disease.